Acute pain is a type of pain that comes on quickly but lasts a short amount of time. Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ... have available," Davis said. Journavx is a drug newly approved ...

Gupta’s comments on CNN’s “The Lead with Jake Tapper” follow Journavx, or suzetrigine ... important public health milestone in acute pain management,” said Jacqueline Corrigan-Curay ...

For the first time in over two decades, the U.S. Food and Drug Administration has approved a new kind of non-opioid drug for pain management. Journavx (suzetrigine), a novel non-opioid medication ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

reinforcing CenExel's commitment to advancing pain management research and delivering high-quality clinical trial execution. "The approval of JOURNAVX represents a monumental step forward in acute ...